CCCC

C4 Therapeutics, Inc.

10.69 USD
+0.01 (+0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

C4 Therapeutics, Inc. stock is up 101.7% since 30 days ago. The next earnings date is May 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 5 CALLs, 5 PUTs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Feb 16:05 18 Oct, 2024 9.00 CALL 395 0
23 Feb 18:26 19 Jul, 2024 9.00 PUT 200 302
23 Feb 18:28 19 Jul, 2024 11.00 PUT 150 0
26 Feb 14:53 15 Mar, 2024 9.50 CALL 250 1
29 Feb 18:13 19 Jul, 2024 11.00 PUT 150 150
29 Feb 18:16 18 Oct, 2024 11.00 PUT 199 0
29 Feb 18:55 19 Jul, 2024 10.00 PUT 150 0
29 Feb 20:56 18 Oct, 2024 12.00 CALL 150 17
04 Mar 14:55 19 Jul, 2024 5.00 CALL 200 825
04 Mar 14:56 19 Jul, 2024 5.00 CALL 100 825

About C4 Therapeutics, Inc.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting multiple myeloma and non-Hodgkin lymphomas. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

  • Morgan Stanley
    Mon Feb 26, 10:40
    hold
    confirm
  • Stifel
    Fri Feb 23, 08:46
    buy
    confirm